Menarini Licenses Preclinical Oral Immunotherapy from Georgiamune

Company Georgiamune; Menarini Group (Stemline) Event Type Exclusive global license Modality Oral small-molecule immunotherapy Asset GIM-621 Target Undisclosed Disease Area Solid tumors Summary Menarini’s Stemline unit licensed global development and commercial rights to preclinical GIM-621. The transaction validates outside interest in Georgiamune’s immune-signaling research, but…